Cell line · CVCL_0179
Papers172
1 to 20 of 172
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Impact of Trastuzumab and Pertuzumab on HER2 Localization and the Estrogen Receptor Cistrome in ER+/HER2+ Breast Cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The role of autoproteolysis and mitoribosomal proteins in the regulation of the mitochondrial LACTB tumor suppressor. | EMBO Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting CD24 Activates Macrophages to Reduce Tumor Burden in Preclinical Models of Solid Tumors. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targetable S100-RAGE Signaling Mediates Intrinsic Trastuzumab Deruxtecan Resistance in Metastatic Breast Cancer. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Distinct metabolic dependency on BCAA defines cancer stemness and malignancy in human triple-negative breast cancer. | Cell Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Single-Cell and Multiomics Characterization of p21 in Cancer Progression and Therapeutic Sensitivity. | Hum Mutat | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Engineering Cathepsin S Selective Chemical Probes and Antibody-Drug Conjugates through Substrate Profiling with Unnatural Amino Acids. | J Med Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combined inhibition of PLK4 and PPM1D promotes cell death in cancer cells with 17q amplification. | Cancer Cell Int | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Hydrostatic pressure activates HIF-1α via β-catenin to promote stemness in breast cancer cells. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Triple-Negative Breast Cancer Cells Utilize IL8 and CXCL1 to Suppress NK Cells' Function and Facilitate Cancer Metastasis. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancer. | Neoplasia | 2026 | Its Methods give the RRID and name the line | PubMed | |
| miR-3648 regulates cell functions and acts as a potential biomarker to predict prognosis in breast cancer and its bioinformatics analysis. | World J Surg Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Integrated Multiomic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Discovery of novel circular RNAs of the apoptosis-related BAX gene in breast cancer, by combining nanopore and next-generation sequencing. | Mol Genet Genomics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting TNBC: core-shell polycationic polyurea dendrimers with inherent anticancer activity. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combinatorial inhibition of IGF2BP3-regulated receptor tyrosine kinases offers a new therapeutic strategy for triple-negative breast cancer. | J Exp Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Junction opener enables CAR T cell treatment of solid tumors. | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Spermine Oxidase Serves as a Key Functional Node in Microbial Dysbiosis-Induced Breast Carcinogenesis. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0179/papers